While the holiday season often brings a lull in action in Washington, D.C. and elsewhere, 2020's was quite different. On the drug pricing front, a major effort by th...

Shanghai Pharmaceuticals—one of two Chinese drugmakers in 2020’s Fortune Global 500—is ringing in the new year with a massive incubation project on its home turf.&nb...

Drugmakers and healthcare providers have been battling for months over 340B discounts on medicines delivered through contract pharmacies, and now HHS has stepped in ...

When AstraZeneca said it would lay out $39 billion for Alexion on Dec. 12—just hours after the first COVID-19 vaccine was approved in the U.S., promising an end to t...

As the chapter closes on the first year of the COVID-19 pandemic, drugmakers are hard at work bolstering the defenses mounted in 2020—and they're looking at new...

After a mutated, fast-spreading variant of COVID-19 in the U.K. disrupted global travel over the weekend, a troubling question emerged: Will the new vaccines from Pf...

Shanghai's WuXi Biologics is ending the year how it started: with plans to take charge at a Bayer facility in Germany. The company's latest site acquisition fol...

Thermo Fisher Scientific is shoring up production of cell and gene therapies on both sides of the pond, a move it hopes will support the development of COV...

Nearly seven years after the largest Ebola epidemic broke out in West Africa, two drugs against the deadly virus are now available. The FDA has approved Ridgeback ...